Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1100652

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1100652

Point of Care Testing Market Size By Product, By Technology, By Prescription, By Application, By End-use, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2022 - 2030

PUBLISHED:
PAGES: 430 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 5350
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

The point of care testing market is expected to witness massive growth through 2030 owing to increasing number of patients with acute illnesses.

Recently, testing in hospitals saw a decline due to the risk of exposure to the novel coronavirus in these settings, which fueled product demand as point of care testing offers flexibility with regards to location. Additionally, rapid testing, a pivotal advantage of point of care assays, has also positively influenced market uptake during the COVID-19 pandemic.

Notably, surging research emphasis by industry players has been beneficial for the product landscape, which has enhanced overall market dynamics. For instance, in June 2022, LumiraDx, a UK-based diagnostics company reported that it had gained CE Mark for its product, the Amira Analyzer. This portable instrument is used for rapid COVID-19 testing.

The point of care testing market has been bifurcated on the basis of technology, application, product, prescription, end-use, and region.

On the basis of product, the market has been bifurcated into cardiometabolic testing products, coagulation testing products, tumor/cancer marker testing products, Drug-of-Abuse (DoA) testing products, cholesterol testing products, glucose monitoring, infectious disease testing products, pregnancy and fertility testing products, urinalysis testing products, hematology testing products, fecal occult testing products, and other products. Among these, the hematology testing products segment was valued at approximately $3,891.7 million in 2021 and is speculated to amass notable gains over 2022-2030.

In terms of technology, the point of care testing market has been segmented into dipsticks, molecular diagnostics, agglutination assays, solid phase, biosensors, flow-through, immunoassays, microfluidics, and lateral flow assays. The molecular diagnostics segment is expected to register a CAGR of around 8.0% over the analysis timeframe.

In context of prescription, the market has been divided into prescription-based testing and OTC testing. The prescription-based testing segment contributed to a market share of roughly 46.1% in 2021 and is estimated to exhibit solid growth in the upcoming time period.

Based on application, the point of care testing market has been divided into infectious disease testing, Drug-of-Abuse (DoA) testing, pregnancy testing, cardio metabolic testing, nephrology testing, blood glucose testing, cancer biomarker testing, and other applications. The infectious disease testing segment is set to witness steady growth, expanding at around 8.1% CAGR through the review period.

On the basis of end-use, the market has been divided into diagnostic centers, home-care settings, hospitals, research laboratories, and others. The research laboratories segment reached more than $4,111.8 million in revenue in 2021.

On the regional front, the point of care testing market in Latin America accounted for nearly 5.8% of the overall industry revenue in 2021. On the other hand, the Middle East & Africa point of care testing industry is set to experience robust growth at a CAGR of about 8.6% over the forecast period.

Product Code: 3086

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definitions
  • 1.2 Base estimates & working
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data Sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Point of care testing industry 360 degree synopsis, 2017 - 2030
    • 2.1.1 Business trends
    • 2.1.2 Product trends
    • 2.1.3 Technology trends
    • 2.1.4 Prescription trends
    • 2.1.5 Application trends
    • 2.1.6 End-use trends
    • 2.1.7 Regional trends

Chapter 3 Point of Care Testing Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2017 - 2030
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Upward trend in disease prevalence among developing countries
      • 3.3.1.2 Surging number of pathology labs and services equipped with advanced diagnostic equipment in North America
      • 3.3.1.3 Technological advancements
      • 3.3.1.4 Increasing R&D investment
      • 3.3.1.5 Growing geriatric population base globally
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 Increasing R&D investment
      • 3.3.2.2 High cost of product development
  • 3.4 Growth potential analysis
    • 3.4.1 By product
    • 3.4.2 By technology
    • 3.4.3 By prescription
    • 3.4.4 By application
    • 3.4.5 By end-use
  • 3.5 COVID-19 impact analysis
  • 3.6 Pricing analysis, by cardiac markers, 2021
  • 3.7 Regulatory landscape
  • 3.8 Technology landscape
  • 3.9 Company share analysis, 2021 (by region)
    • 3.9.1 Global market share analysis, 2021
    • 3.9.2 North America
    • 3.9.3 Europe
    • 3.9.4 Asia Pacific
    • 3.9.5 Latin America
    • 3.9.6 MEA
  • 3.10 Porter's analysis
  • 3.11 Competitive landscape, 2021
    • 3.11.1 Company matrix analysis, 2021
  • 3.12 PESTEL analysis

Chapter 4 Point of Care Testing Market, By Product

  • 4.1 Key segment trends
  • 4.2 Glucose monitoring
    • 4.2.1 Market size, by region, 2017 - 2030 (USD Million)
    • 4.2.2 Strips
      • 4.2.2.1 Market size, by region, 2017 - 2030 (USD Million)
    • 4.2.3 Meters
      • 4.2.3.1 Market size, by region, 2017 - 2030 (USD Million)
    • 4.2.4 Lancets
      • 4.2.4.1 Market size, by region, 2017 - 2030 (USD Million)
  • 4.3 Cardiometabolic testing products
    • 4.3.1 Market size, by region, 2017 - 2030 (USD Million)
    • 4.3.2 Cardiac marker testing products
      • 4.3.2.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.2.2 High sensitivity troponin I (hsTnI)
        • 4.3.2.2.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.2.3 Brain natriuretic peptide (BNP)
        • 4.3.2.3.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.2.4 D-dimer
        • 4.3.2.4.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.2.5 Creatine kinase-MB (CK-MB)
        • 4.3.2.5.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.2.6 Myoglobin
        • 4.3.2.6.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.2.7 Others
        • 4.3.2.7.1 Market size, by region, 2017-2030 (USD Million)
    • 4.3.3 Blood Gas/Electrolytes testing products
      • 4.3.3.1 Market size, by region, 2017-2030 (USD Million)
    • 4.3.4 HBA1C testing products
      • 4.3.4.1 Market size, by region, 2017-2030 (USD Million)
  • 4.4 Infectious disease testing products
    • 4.4.1 Market size, by region, 2017-2030 (USD Million)
    • 4.4.2 Influenza testing products
      • 4.4.2.1 Market size, by region, 2017-2030 (USD Million)
    • 4.4.3 HIV testing products
      • 4.4.3.1 Market size, by region, 2017-2030 (USD Million)
    • 4.4.4 Hepatitis C testing products
      • 4.4.4.1 Market size, by region, 2017-2030 (USD Million)
    • 4.4.5 Sexually transmitted disease (STD) testing products
      • 4.4.5.1 Market size, by region, 2017-2030 (USD Million)
    • 4.4.6 Healthcare-associated Infection (HAI) testing products
      • 4.4.6.1 Market size, by region, 2017-2030 (USD Million)
    • 4.4.7 Respiratory infection testing products
      • 4.4.7.1 Market size, by region, 2017-2030 (USD Million)
    • 4.4.8 Tropical disease testing products
      • 4.4.8.1 Market size, by region, 2017-2030 (USD Million)
    • 4.4.9 Other infectious diseases testing products
      • 4.4.9.1 Market size, by region, 2017-2030 (USD Million)
  • 4.5 Coagulation testing products
    • 4.5.1 Market size, by region, 2017-2030 (USD Million)
    • 4.5.2 PT/INR testing products
      • 4.5.2.1 Market size, by region, 2017-2030 (USD Million)
    • 4.5.3 Activated clotting time (ACT/APTT) testing products
      • 4.5.3.1 Market size, by region, 2017-2030 (USD Million)
  • 4.6 Pregnancy & fertility testing products
    • 4.6.1 Market size, by region, 2017-2030 (USD Million)
    • 4.6.2 Pregnancy testing products
      • 4.6.2.1 Market size, by region, 2017-2030 (USD Million)
    • 4.6.3 Fertility testing products
      • 4.6.3.1 Market size, by region, 2017-2030 (USD Million)
  • 4.7 Tumor/Cancer marker testing products
    • 4.7.1 Market size, by region, 2017-2030 (USD Million)
  • 4.8 Cholesterol testing products
    • 4.8.1 Market size, by region, 2017-2030 (USD Million)
  • 4.9 Hematology testing products
    • 4.9.1 Market size, by region, 2017-2030 (USD Million)
  • 4.10 Drug-of-Abuse (DoA) testing products
    • 4.10.1 Market size, by region, 2017-2030 (USD Million)
  • 4.11 Fecal occult testing products
    • 4.11.1 Market size, by region, 2017-2030 (USD Million)
  • 4.12 Urinalysis testing products
    • 4.12.1 Market size, by region, 2017-2030 (USD Million)
  • 4.13 Other products
    • 4.13.1 Market size, by region, 2017-2030 (USD Million)

Chapter 5 Point of Care Testing Market, By Technology

  • 5.1 Key segment trends
  • 5.2 Lateral flow assays
    • 5.2.1 Market size, by region, 2017 - 2030 (USD Million)
  • 5.3 Dipsticks
    • 5.3.1 Market size, by region, 2017 - 2030 (USD Million)
  • 5.4 Microfluidics
    • 5.4.1 Market size, by region, 2017 - 2030 (USD Million)
  • 5.5 Molecular diagnostics
    • 5.5.1 Market size, by region, 2017 - 2030 (USD Million)
  • 5.6 Immunoassays
    • 5.6.1 Market size, by region, 2017 - 2030 (USD Million)
  • 5.7 Agglutination assays
    • 5.7.1 Market size, by region, 2017 - 2030 (USD Million)
  • 5.8 Flow-through
    • 5.8.1 Market size, by region, 2017 - 2030 (USD Million)
  • 5.9 Solid phase
    • 5.9.1 Market size, by region, 2017 - 2030 (USD Million)
  • 5.10 Biosensors
    • 5.10.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 6 Point of Care Testing Market, By Prescription

  • 6.1 Key segment trends
  • 6.2 OTC testing
    • 6.2.1 Market size, by region, 2017 - 2030 (USD Million)
  • 6.3 Prescription-based testing
    • 6.3.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 7 Point of Care Testing Market, By Application

  • 7.1 Key segment trends
  • 7.2 Cardio metabolic testing
    • 7.2.1 Market size, by region, 2017 - 2030 (USD Million)
  • 7.3 Infectious disease testing
    • 7.3.1 Market size, by region, 2017 - 2030 (USD Million)
  • 7.4 Nephrology testing
    • 7.4.1 Market size, by region, 2017 - 2030 (USD Million)
  • 7.5 Drug-of-Abuse (DoA) testing
    • 7.5.1 Market size, by region, 2017 - 2030 (USD Million)
  • 7.6 Blood glucose testing
    • 7.6.1 Market size, by region, 2017 - 2030 (USD Million)
  • 7.7 Pregnancy testing
    • 7.7.1 Market size, by region, 2017 - 2030 (USD Million)
  • 7.8 Cancer biomarker testing
    • 7.8.1 Market size, by region, 2017 - 2030 (USD Million)
  • 7.9 Other applications
    • 7.9.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 8 Point of Care Testing Market, By End-use

  • 8.1 Key segment trends
  • 8.2 Hospitals
    • 8.2.1 Market size, by region, 2017 - 2030 (USD Million)
  • 8.3 Diagnostic centers
    • 8.3.1 Market size, by region, 2017 - 2030 (USD Million)
  • 8.4 Research laboratories
    • 8.4.1 Market size, by region, 2017 - 2030 (USD Million)
  • 8.5 Home-care settings
    • 8.5.1 Market size, by region, 2017 - 2030 (USD Million)
  • 8.6 other
    • 8.6.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 9 Point of Care Testing Market, By Region

  • 9.1 Key regional trends
  • 9.2 North America
    • 9.2.1 Market size, by country, 2017 - 2030 (USD Million)
    • 9.2.2 Market size, by product, 2017 - 2030 (USD Million)
      • 9.2.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
      • 9.2.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.2.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
      • 9.2.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
      • 9.2.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
      • 9.2.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
    • 9.2.3 Market size, by technology, 2017 - 2030 (USD Million)
    • 9.2.4 Market size, by prescription, 2017 - 2030 (USD Million)
    • 9.2.5 Market size, by application, 2017 - 2030 (USD Million)
    • 9.2.6 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.2.7 U.S.
      • 9.2.7.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.2.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.2.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.2.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.2.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.2.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.2.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.2.7.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.2.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.2.7.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.2.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.2.8 Canada
      • 9.2.8.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.2.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.2.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.2.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.2.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.2.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.2.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.2.8.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.2.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.2.8.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.2.8.5 Market size, by end-use, 2017 - 2030 (USD Million)
  • 9.3 Europe
    • 9.3.1 Market size, by country, 2017 - 2030 (USD Million)
    • 9.3.2 Market size, by product, 2017 - 2030 (USD Million)
      • 9.3.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
      • 9.3.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.3.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
      • 9.3.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
      • 9.3.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
      • 9.3.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
    • 9.3.3 Market size, by technology, 2017 - 2030 (USD Million)
    • 9.3.4 Market size, by prescription, 2017 - 2030 (USD Million)
    • 9.3.5 Market size, by application, 2017 - 2030 (USD Million)
    • 9.3.6 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.3.7 Germany
      • 9.3.7.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.3.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.3.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.3.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.3.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.3.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.3.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.3.7.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.3.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.3.7.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.3.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.3.8 UK
      • 9.3.8.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.3.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.3.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.3.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.3.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.3.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.3.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.3.8.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.3.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.3.8.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.3.8.5 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.3.9 France
      • 9.3.9.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.3.9.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.3.9.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.3.9.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.3.9.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.3.9.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.3.9.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.3.9.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.3.9.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.3.9.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.3.9.5 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.3.10 Spain
      • 9.3.10.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.3.10.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.3.10.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.3.10.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.3.10.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.3.10.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.3.10.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.3.10.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.3.10.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.3.10.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.3.10.5 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.3.11 Italy
      • 9.3.11.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.3.11.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.3.11.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.3.11.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.3.11.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.3.11.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.3.11.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.3.11.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.3.11.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.3.11.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.3.11.5 Market size, by end-use, 2017 - 2030 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Market size, by country, 2017 - 2030 (USD Million)
    • 9.4.2 Market size, by product, 2017 - 2030 (USD Million)
      • 9.4.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
      • 9.4.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.4.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
      • 9.4.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
      • 9.4.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
      • 9.4.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
    • 9.4.3 Market size, by technology, 2017 - 2030 (USD Million)
    • 9.4.4 Market size, by prescription, 2017 - 2030 (USD Million)
    • 9.4.5 Market size, by application, 2017 - 2030 (USD Million)
    • 9.4.6 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.4.7 China
      • 9.4.7.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.4.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.4.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.4.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.4.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.4.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.4.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.4.7.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.4.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.4.7.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.4.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.4.8 India
      • 9.4.8.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.4.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.4.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.4.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.4.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.4.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.4.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.4.8.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.4.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.4.8.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.4.8.5 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.4.9 Japan
      • 9.4.9.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.4.9.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.4.9.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.4.9.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.4.9.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.4.9.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.4.9.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.4.9.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.4.9.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.4.9.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.4.9.5 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.4.10 Australia
      • 9.4.10.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.4.10.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.4.10.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.4.10.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.4.10.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.4.10.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.4.10.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.4.10.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.4.10.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.4.10.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.4.10.5 Market size, by end-use, 2017 - 2030 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Market size, by country, 2017 - 2030 (USD Million)
    • 9.5.2 Market size, by product, 2017 - 2030 (USD Million)
      • 9.5.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
      • 9.5.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.5.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
      • 9.5.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
      • 9.5.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
      • 9.5.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
    • 9.5.3 Market size, by technology, 2017 - 2030 (USD Million)
    • 9.5.4 Market size, by prescription, 2017 - 2030 (USD Million)
    • 9.5.5 Market size, by application, 2017 - 2030 (USD Million)
    • 9.5.6 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.5.7 Brazil
      • 9.5.7.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.5.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.5.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.5.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.5.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.5.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.5.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.5.7.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.5.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.5.7.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.5.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.5.8 Mexico
      • 9.5.8.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.5.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.5.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.5.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.5.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.5.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.5.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.5.8.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.5.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.5.8.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.5.8.5 Market size, by end-use, 2017 - 2030 (USD Million)
  • 9.6 MEA
    • 9.6.1 Market size, by country, 2017 - 2030 (USD Million)
    • 9.6.2 Market size, by product, 2017 - 2030 (USD Million)
      • 9.6.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
      • 9.6.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.6.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
      • 9.6.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
      • 9.6.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
      • 9.6.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
    • 9.6.3 Market size, by technology, 2017 - 2030 (USD Million)
    • 9.6.4 Market size, by prescription, 2017 - 2030 (USD Million)
    • 9.6.5 Market size, by application, 2017 - 2030 (USD Million)
    • 9.6.6 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.6.7 South Africa
      • 9.6.7.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.6.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.6.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.6.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.6.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.6.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.6.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.6.7.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.6.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.6.7.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.6.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
    • 9.6.8 Saudi Arabia
      • 9.6.8.1 Market size, by product, 2017 - 2030 (USD Million)
        • 9.6.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
        • 9.6.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
        • 9.6.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
        • 9.6.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
        • 9.6.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
        • 9.6.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
      • 9.6.8.2 Market size, by technology, 2017 - 2030 (USD Million)
      • 9.6.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
      • 9.6.8.4 Market size, by application, 2017 - 2030 (USD Million)
      • 9.6.8.5 Market size, by end-use, 2017 - 2030 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Competitive dashboard
  • 10.2 Abaxis
    • 10.2.1 Business overview
    • 10.2.2 Financial data
    • 10.2.3 Product landscape
    • 10.2.4 Strategic outlook
    • 10.2.5 SWOT analysis
  • 10.3 Abbott
    • 10.3.1 Business overview
    • 10.3.2 Financial data
    • 10.3.3 Product landscape
    • 10.3.4 Strategic outlook
    • 10.3.5 SWOT analysis
  • 10.4 Accubiotech Co, Ltd.
    • 10.4.1 Business overview
    • 10.4.2 Financial data
    • 10.4.3 Product landscape
    • 10.4.4 Strategic outlook
    • 10.4.5 SWOT analysis
  • 10.5 ACON Laboratories, Inc
    • 10.5.1 Business overview
    • 10.5.2 Financial data
    • 10.5.3 Product landscape
    • 10.5.4 Strategic outlook
    • 10.5.5 SWOT analysis
  • 10.6 Becton, Dickinson and Company
    • 10.6.1 Business overview
    • 10.6.2 Financial data
    • 10.6.3 Product landscape
    • 10.6.4 Strategic outlook
    • 10.6.5 SWOT analysis
  • 10.7 bioLytical Laboratories Inc
    • 10.7.1 Business overview
    • 10.7.2 Financial data
    • 10.7.3 Product landscape
    • 10.7.4 Strategic outlook
    • 10.7.5 SWOT analysis
  • 10.8 BioMrieux SA
    • 10.8.1 Business overview
    • 10.8.2 Financial data
    • 10.8.3 Product landscape
    • 10.8.4 Strategic outlook
  • 10.9 Bio-Rad Laboratories, Inc
    • 10.9.1 Business overview
    • 10.9.2 Financial data
    • 10.9.3 Product landscape
    • 10.9.4 Strategic outlook
    • 10.9.5 SWOT analysis
  • 10.10 HemoCue AB (Danaher Corporation)
    • 10.10.1 Business overview
    • 10.10.2 Financial data
    • 10.10.3 Product landscape
    • 10.10.4 Strategic outlook
    • 10.10.5 SWOT analysis
  • 10.11 Dexcom, Inc
    • 10.11.1 Business overview
    • 10.11.2 Financial data
    • 10.11.3 Product landscape
    • 10.11.4 Strategic outlook
    • 10.11.5 SWOT analysis
  • 10.12 Dragerwerk Ag & Co
    • 10.12.1 Business overview
    • 10.12.2 Financial data
    • 10.12.3 Product landscape
    • 10.12.4 Strategic outlook
    • 10.12.5 SWOT analysis
  • 10.13 LifeScan IP Holdings, LLC
    • 10.13.1 Business overview
    • 10.13.2 Financial data
    • 10.13.3 Product landscape
    • 10.13.4 Strategic outlook
    • 10.13.5 SWOT analysis
  • 10.14 Medtronic plc
    • 10.14.1 Business overview
    • 10.14.2 Financial data
    • 10.14.3 Product landscape
    • 10.14.4 Strategic outlook
    • 10.14.5 SWOT analysis
  • 10.15 Meridian Bioscience, Inc
    • 10.15.1 Business overview
    • 10.15.2 Financial data
    • 10.15.3 Product landscape
    • 10.15.4 Strategic outlook
    • 10.15.5 SWOT analysis
  • 10.16 Nova Biomedical
    • 10.16.1 Business overview
    • 10.16.2 Financial data
    • 10.16.3 Product landscape
    • 10.16.4 Strategic outlook
    • 10.16.5 SWOT analysis
  • 10.17 OraSure Technologies, Inc
    • 10.17.1 Business overview
    • 10.17.2 Financial data
    • 10.17.3 Product landscape
    • 10.17.4 Strategic outlook
    • 10.17.5 SWOT analysis
  • 10.18 F. Hoffmann-La Roche
    • 10.18.1 Business overview
    • 10.18.2 Financial data
    • 10.18.3 Product landscape
    • 10.18.4 Strategic outlook
    • 10.18.5 SWOT analysis
  • 10.19 Siemens Healthineers AG
    • 10.19.1 Business overview
    • 10.19.2 Financial data
    • 10.19.3 Product landscape
    • 10.19.4 Strategic outlook
    • 10.19.5 SWOT analysis
  • 10.20 Sysmex Corporation
    • 10.20.1 Business overview
    • 10.20.2 Financial data
    • 10.20.3 Product landscape
    • 10.20.4 Strategic outlook
    • 10.20.5 SWOT analysis
  • 10.21 Trinity Biotech
    • 10.21.1 Business overview
    • 10.21.2 Financial data
    • 10.21.3 Product landscape
    • 10.21.4 Strategic outlook
    • 10.21.5 SWOT analysis
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!